New investments broaden global health commitments in Japan
The fund has invested an additional $10.7 million in several areas throughout the product pipeline, including in projects for leishmaniasis, tuberculosis (TB), dengue, and malaria.
This is an important time for projects for these four illnesses. Vaccines and novel treatments for malaria and TB are needed because of an increase in drug resistance. In addition, dengue fever infections have increased around the world, and there are not yet any vaccines or drugs that can prevent this disease. Leishmaniasis is expected to increase as well because of the chaos and fear in Iraq and Syria.
"We are excited about this latest round of investments as they showcase our aggressive 'Hit-to-Lead Platform' for advancing potentially promising new interventions that have been identified through our screening platform," GHIT Fund's Chief Executive Officer BT Slingsby said. "We're also funding five new projects through our Product Development Platform and rolling out our inaugural investments in our Grand Challenges program. Through these distinctly different initiatives, GHIT is establishing an effective, efficient and multifaceted process for harnessing Japanese innovation to fight diseases that are a major source of illness in the developing world."